{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:40:26Z","timestamp":1764603626111,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T00:00:00Z","timestamp":1578096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T00:00:00Z","timestamp":1578096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81603081"],"award-info":[{"award-number":["81603081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Key Science-Technology Research and Development Program of Hunan Province","award":["2016JC2062"],"award-info":[{"award-number":["2016JC2062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12325-019-01214-y","type":"journal-article","created":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T14:02:57Z","timestamp":1578146577000},"page":"847-859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Yin","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongqing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-3910","authenticated-orcid":false,"given":"Liubao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,4]]},"reference":[{"key":"1214_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, et al. Cancer statistics in China. CA Cancer J Clin. 2016;66:115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 5","key":"1214_CR2","doi-asserted-by":"publisher","first-page":"v93","DOI":"10.1093\/annonc\/mdq222","volume":"21","author":"E Van Cutsem","year":"2010","unstructured":"Van Cutsem E, Nordlinger B, Cervantes A, et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol. 2010;21(Suppl 5):v93\u20137.","journal-title":"Ann Oncol"},{"key":"1214_CR3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/ijc.26192","volume":"131","author":"H Brenner","year":"2012","unstructured":"Brenner H, Bouvier AM, Foschi R, et al. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer. 2012;131:1649\u201358.","journal-title":"Int J Cancer"},{"key":"1214_CR4","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Colon Cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed 13 Dec 2018."},{"key":"1214_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andr\u00e9 T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229\u201337.","journal-title":"J Clin Oncol"},{"key":"1214_CR6","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658\u201364.","journal-title":"J Clin Oncol"},{"key":"1214_CR7","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706\u201313.","journal-title":"J Clin Oncol"},{"key":"1214_CR8","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-15-0526","volume":"21","author":"M Peeters","year":"2015","unstructured":"Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS\/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res. 2015;21:5469\u201379.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"1214_CR9","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1002\/cncr.30666","volume":"123","author":"XM Wan","year":"2017","unstructured":"Wan XM, Peng LB, Ma JA, et al. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. Cancer. 2017;123(14):2634\u201341.","journal-title":"Cancer"},{"key":"1214_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","volume":"14","author":"M Hoyle","year":"2011","unstructured":"Hoyle M, Rogers G, Moxham T, et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health. 2011;14:1057\u201367.","journal-title":"Value Health."},{"key":"1214_CR11","first-page":"23","volume-title":"China Guidelines for Pharmcoeconomic Evaluation","author":"China Guidelines for Pharmcoeconomic Evaluation research group","year":"2011","unstructured":"China Guidelines for Pharmcoeconomic Evaluation research group. China Guidelines for Pharmcoeconomic Evaluation. 1st ed. Beijing: China Center for Health Economic Research; 2011. p. 23\u20134.","edition":"1"},{"key":"1214_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2288-11-139","volume":"11","author":"MW Hoyle","year":"2011","unstructured":"Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.","journal-title":"BMC Med Res Methodol"},{"key":"1214_CR13","doi-asserted-by":"publisher","first-page":"e0121353","DOI":"10.1371\/journal.pone.0121353","volume":"10","author":"X Wan","year":"2015","unstructured":"Wan X, Peng L, Li Y. A review and comparison of methods for recreating individual patient data from published Kaplan\u2013Meier survival curves for economic evaluations: a simulation study. PLoS One. 2015;10:e0121353.","journal-title":"PLoS One"},{"key":"1214_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19910","volume":"19","author":"K Freeman","year":"2015","unstructured":"Freeman K, Connock M, Cummins E, et al. Fluorouracil plasma monitoring: the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. Health Technol Assess. 2015;19:1\u2013321 (v\u2013vi).","journal-title":"Health Technol Assess"},{"key":"1214_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40273-018-0630-9","volume":"36","author":"IA Tikhonova","year":"2018","unstructured":"Tikhonova IA, Huxley N, Snowsill T, et al. Economic analysis of first-line treatment with cetuximab or panitumumab for RAS wild-type metastatic colorectal cancer in England. Pharmacoeconomics. 2018;36:837\u201351.","journal-title":"Pharmacoeconomics."},{"key":"1214_CR16","doi-asserted-by":"publisher","first-page":"e32530","DOI":"10.1371\/journal.pone.0032530","volume":"7","author":"B Wu","year":"2012","unstructured":"Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a healthresource-limited setting. PLoS One. 2012;7:e32530.","journal-title":"PLoS One."},{"key":"1214_CR17","first-page":"1795","volume":"33","author":"L Li-xia","year":"2013","unstructured":"Li-xia L, Shu-hone B, Lan J, et al. Analysis on ADR treatment cost of the four chemotherapy regimens for colorectal cancer [Article in Chinese]. Zhongguo Yiyuan Yaoxue Zazhi. 2013;33:1795\u20138.","journal-title":"Zhongguo Yiyuan Yaoxue Zazhi"},{"key":"1214_CR18","first-page":"657","volume":"32","author":"W Xiao-hui","year":"2012","unstructured":"Xiao-hui W, Jun Z, Dong Z. Pharmacoeconomic research on adverse drug reactions of chemotherapy for lung cancer [Article in Chinese]. J Shanghai Jiaotong Univ. 2012;32:657\u201360.","journal-title":"J Shanghai Jiaotong Univ"},{"key":"1214_CR19","first-page":"91","volume":"12","author":"J Yu-ming","year":"2001","unstructured":"Yu-ming J, Jun P, Ziping L, et al. Pharmacoeconomic research on adverse drug reactions of chemotherapy for lung cancer [Article in Chinese]. China Pharm. 2001;12:91\u20132.","journal-title":"China Pharm"},{"key":"1214_CR20","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bjc.2011.409","volume":"105","author":"L Bennett","year":"2011","unstructured":"Bennett L, Zhao Z, Barber B, et al. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Br J Cancer. 2011;105:1495\u2013502.","journal-title":"Br J Cancer"},{"key":"1214_CR21","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/bjc.2011.179","volume":"104","author":"J Wang","year":"2011","unstructured":"Wang J, Zhao Z, Barber B, et al. A Q-twist analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer. 2011;104:1848\u201353.","journal-title":"Br J Cancer"},{"key":"1214_CR22","unstructured":"National Bureau of Statistics of China. Health care and personal articles of consumer price indices. http:\/\/data.stats.gov.cn\/search.htm?s=CPI. Accessed 20 July 2019."},{"key":"1214_CR23","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2014.58.4904","volume":"33","author":"DA Goldstein","year":"2015","unstructured":"Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol. 2015;33:1112\u20138.","journal-title":"J Clin Oncol"},{"key":"1214_CR24","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modeling for Health Economic Evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton C, Sculpher M. Decision Modeling for Health Economic Evaluation. Oxford, England: Oxford University Press; 2006."},{"key":"1214_CR25","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1158\/0008-5472.CAN-15-3179","volume":"76","author":"A Ocana","year":"2016","unstructured":"Ocana A, Amir E, Tannock IF. Toward value-based pricing to boost cancer research and innovation. Cancer Res. 2016;76:3127\u20139.","journal-title":"Cancer Res"},{"key":"1214_CR26","unstructured":"National Institute for Health and Care Excellence. Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer [ID794]. https:\/\/www.nice.org.theUK\/guidance\/ta439\/evidence. Accessed 14 May 2018."},{"key":"1214_CR27","unstructured":"World Health Organization. Choosing Interventions that are Cost Effective (WHO-CHOICE), Tables of costs and prices used in WHO-CHOICE analysis. https:\/\/www.who.int\/entity\/choice\/costs\/en\/. Accessed 04 Sep 2019."},{"key":"1214_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518\u201328.","journal-title":"Value Health."},{"key":"1214_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O","volume":"9","author":"CJ Murray","year":"2000","unstructured":"Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9:235\u201351 (8.38).","journal-title":"Health Econ"},{"key":"1214_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/jama.2014.17814","volume":"313","author":"A Messori","year":"2015","unstructured":"Messori A, De Rosa M, Pani L. Alternative pricing strategies for cancer drugs. JAMA. 2015;313:857.","journal-title":"JAMA"},{"key":"1214_CR31","unstructured":"The Economist Intelligence Unit. Valuebased healthcare in France: a slow adoption of cost-effectiveness criteria. http:\/\/www.economistinsights.com\/sites\/default\/files\/ValuebasedhealthcareFrance.pdf. Accessed 9 Dec 2019."},{"key":"1214_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2165\/11592580-000000000-00000","volume":"29","author":"A Gerber","year":"2011","unstructured":"Gerber A, Stock S, Dintsios CM. Reflections on the changing face of German pharmaceutical policy: How far is Germany from value-based pricing? Pharmacoeconomics. 2011;29:549\u201353.","journal-title":"Pharmacoeconomics."},{"issue":"8","key":"1214_CR33","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1634\/theoncologist.2016-0106","volume":"21","author":"DA Goldstein","year":"2016","unstructured":"Goldstein DA, Sarfaty M. Cancer drug pricing and reimbursement: lessons for the United States from around the world. Oncologist. 2016;21(8):907\u20139.","journal-title":"Oncologist."},{"key":"1214_CR34","doi-asserted-by":"publisher","first-page":"A821","DOI":"10.1016\/j.jval.2015.09.260","volume":"18","author":"RF Dos Santos","year":"2015","unstructured":"Dos Santos RF, Coutinho MB, Haas L. Panitumumab\u2009+\u2009Mfolfox6 versus bevacizumab\u2009+\u2009Mfolfox6 as first-line treatment of wild-type Ras metastatic colorectal cancer: a cost-effectiveness analysis from the Brazilian Private Healthcare System Perspective. Value Health. 2015;18:A821.","journal-title":"Value Health."},{"key":"1214_CR35","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.ejca.2014.08.016","volume":"50","author":"CN Graham","year":"2014","unstructured":"Graham CN, Hechmati G, Hjelmgren J, et al. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014;50:2791\u2013801.","journal-title":"Eur J Cancer"},{"key":"1214_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.14735\/amko2015265","volume":"28","author":"J F\u00ednek","year":"2015","unstructured":"F\u00ednek J, Skoup\u00e1 J, Jandov\u00e1 P. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer-Czech Republic model adaptation. Klin Onkol. 2015;28:265\u201372.","journal-title":"Klin Onkol."},{"key":"1214_CR37","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.3747\/co.21.1837","volume":"21","author":"EM Ewara","year":"2014","unstructured":"Ewara EM, Zaric GS, Welch S, et al. Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer. Curr Oncol. 2014;21:e541\u201350.","journal-title":"Curr Oncol."},{"key":"1214_CR38","doi-asserted-by":"publisher","first-page":"A460","DOI":"10.1016\/j.jval.2015.09.1187","volume":"18","author":"J Suarez","year":"2015","unstructured":"Suarez J. Cost-effectiveness analysis of cetuximab and panitumumab for first line treatment of metastatic colorectal cancer (Mcrc) in Wt Ras patients in Spain. Value Health. 2015;18:A460.","journal-title":"Value Health."},{"key":"1214_CR39","doi-asserted-by":"publisher","first-page":"A460","DOI":"10.1016\/j.jval.2015.09.1188","volume":"18","author":"J Vargas-Valencia","year":"2015","unstructured":"Vargas-Valencia J, Garcia Perlaza J. Cost-effectiveness analysis of Panitumumab\u2009+\u2009Folfox compared to Cetuximab\u2009+\u2009Folfiri as first-line treatment for patients with wild-type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) metastatic colorectal cancer (Mcrc) in Colombia. Value Health. 2015;18:A460.","journal-title":"Value Health."},{"key":"1214_CR40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jval.2012.11.001","volume":"16","author":"M Hoyle","year":"2013","unstructured":"Hoyle M, Peters J, Crathorne L, et al. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Value Health. 2013;16:288\u201396.","journal-title":"Value Health."},{"key":"1214_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","volume":"12","author":"M Drummond","year":"2009","unstructured":"Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12:409\u201318.","journal-title":"Value Health."},{"key":"1214_CR42","unstructured":"National Development and Reform Commission. Abolishment of government (guided) pricing for the majority of drugs and push to the drug pricing reform [in Chinese]. http:\/\/www.sdpc.gov.cn\/xwzx\/xwfb\/201505\/t20150505_690687.html. Accessed 13 Dec 2018."},{"key":"1214_CR43","unstructured":"State Council of the People\u2019s Republic of China. China to cut prices of expensive patent drugs [in Chinese]. http:\/\/english.gov.cn\/news\/top_news\/2016\/05\/20\/content_281475353689066.html. Accessed 13 Dec 2018."},{"key":"1214_CR44","unstructured":"State Council of the People\u2019s Republic of China. Notice of the State Council on issuing the 13th five-year plan on deepening the medical and health care system reform [in Chinese]. http:\/\/www.gov.cn\/zhengce\/content\/2017-01\/09\/content_5158053.html. Accessed 13 Dec 2018."},{"key":"1214_CR45","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/hec.1625","volume":"20","author":"N Hawkins","year":"2011","unstructured":"Hawkins N, Scott DA. Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word. Health Econ. 2011;20:688\u201398.","journal-title":"Health Econ"},{"key":"1214_CR46","unstructured":"Ministry of Finance of the People\u2019s Republic of China. Notice of the policy of added-value tax on anti-cancer drugs [in Chinese]. http:\/\/szs.mof.gov.cn\/zhengwuxinxi\/zhengcefabu\/201804\/t20180427_2880407.html. Accessed 13 Dec 2018."},{"key":"1214_CR47","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10549-008-0035-0","volume":"114","author":"SG Lee","year":"2009","unstructured":"Lee SG, Jee YG, Chung HC, et al. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluororacil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat. 2009;114:589\u201395.","journal-title":"Breast Cancer Res Treat"},{"key":"1214_CR48","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2165\/11314750-000000000-00000","volume":"27","author":"P Liubao","year":"2009","unstructured":"Liubao P, Xiaomin W, Chongqing T, et al. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide. Pharmacoeconomics. 2009;27:873\u201386.","journal-title":"Pharmacoeconomics."},{"key":"1214_CR49","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/jamaoncol.2015.3316","volume":"1","author":"DA Goldstein","year":"2015","unstructured":"Goldstein DA, Chen Q, Ayer T, et al. Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol. 2015;1:1293\u2013300.","journal-title":"JAMA Oncol."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01214-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T19:06:53Z","timestamp":1722280013000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01214-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01214-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2020,1,4]]},"assertion":[{"value":"24 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}